Atopic Dermatitis Market
Atopic Dermatitis Market Study by Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Biologic Therapies, PDE-4 Inhibitors, Antibiotics, Antihistamines, and Emollients from 2024 to 2034
Analysis of Atopic Dermatitis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Atopic Dermatitis Market Outlook (2024 to 2034)
According to a report by the International Eczema Council, around 223 million individuals across the globe were experiencing atopic dermatitis in 2022. With the global atopic dermatitis market placed at US$ 12.73 billion in 2024, companies can expect market expansion at a CAGR of 4.3% and a valuation of US$ 19.49 billion by the end of 2034.
Atopic dermatitis widely known as eczema is a skin disorder that causes irritation, redness, and inflammation to the skin. Rising prevalence of eczema is contributing to the market growth. Increasing awareness of skin disorders, a high need for quick detection, and rising popularity of biological drugs are all driving the business ahead.
Global atopic dermatitis market growth is expected to be driven by the emergence of the latest technologies in the medical sector and the introduction of innovative procedures. The rising use of harsh soaps, shampoos, and hand wash are leading to the development of skin conditions such as eczema. This aspect is driving key market players to produce innovative atopic dermatitis solutions such as moisturizers and ointments with escalating healing properties.
- Increasing cases of hand atopic dermatitis are expected to push the North American atopic dermatitis market size to US$ 6.44 billion by 2034.
- Western Europe is estimated to hold 21.7% of the global atopic dermatitis market share in 2024.
| Report Attributes | Details |
|---|---|
| Atopic Dermatitis Market Size (2024E) | US$ 12.73 Billion |
| Forecasted Market Value (2034F) | US$ 19.49 Billion |
| Global Market Growth Rate (2024 to 2034) | 4.3% CAGR |
| South Korea Market Value (2034F) | US$ 837.2 Million |
| Sales of Corticosteroids (2034F) | US$ 4.72 Billion |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How is the Market for Atopic Dermatitis Solutions Evolving?
“Rising Prevalence of Skin Disorders Increasing Need for Modern Dermatological Products”
Dermatological disorders are highly prevalent in various forms across the globe.
- According to the World Health Organization 2023 report, around 1.8 billion people across the globe are living with skin disorders. Viral, bacterial, fungal or parasitic origin, are the most prevalent cause of skin diseases.
Increasing incidence of skin disorders are expected to generate lucrative opportunities for atopic dermatitis solution manufacturers during the coming decade. Other factors, such as the development of novel pipeline drugs and rising demand for subcutaneous biologics and product approvals, are also expected to increase the growth of the atopic dermatitis market throughout the forecast period.
“Technological Advancements Leading to Development of Novel Drugs”
Increasing sales of atopic dermatitis drugs are driven by the emergence of the latest technologies in the healthcare sector and the introduction of innovative procedures.
Rising acceptance and quick expansion of the novel treatment in the emerging economies are expected to boost the demand for skincare ingredients throughout the forecast period. Leading companies are concentrating their efforts on the unveiling of new novel formulations by investing heavily in research and development activities.
- For instance, in January 2022, USFDA approved AbbVie's Rinvoq and Pfizer's Cibinqo to treat moderate-to-severe atopic dermatitis, or eczema, in patients unable to respond to the previous treatments.
What’s Hampering Adoption of Atopic Dermatitis Drugs to Some Extent?
“Lack of Awareness and High Treatment Costs”
Some of the factors hampering the adoption of atopic dermatitis drugs in the underdeveloped countries is due to the lack of awareness, cultural taboo towards skin disorders, high treatment cost, and absence of reimbursement policies. The treatment cost of atopic dermatitis treatment is still a deterrent to its adoption among low-income individuals. Furthermore, stringent regulations for product approvals in some regions are also limiting atopic dermatitis drug sales.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Startup Ecosystem
Arcutis Biotherapeutics is a start-up established in the year 2016 with 50+ FDA products. The company focuses on efficacy, safety, and tolerability for disease management and drug optimization. Its commitment towards innovations is leading to the development of novel drugs for the treatment of immune-mediated skin diseases, including seborrheic dermatitis, atopic dermatitis, plaque psoriasis, and scalp psoriasis.
- In November, 2022 - Arcutis Biotherapeutics, Inc. announced positive excellent outcome from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, in adults and children six years and older with mild to moderate atopic dermatitis (AD).
Country-wise Analysis
What is the Sales Outlook for Atopic Dermatitis Drugs in the United States?
“High Cases of Eczema Leading to Production of Advanced Drugs”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 3.9 Billion |
| Growth Rate (2024 to 2034) | 3.6% CAGR |
| Projected Value (2034F) | US$ 5.58 Billion |
The United States market is anticipated to maintain its supremacy in North America throughout the forecast period. This can be attributed to the presence of early adopters of advanced products, adequate reimbursement coverage for pharmaceutical companies, and presence of key market players. Also, growing cases of skin diseases across all age groups in the United States are poised to create profitable opportunities for atopic dermatitis drug manufacturers.
- According to National Eczema Association, around 31.6 million Americans are living with some form of eczema.
- The U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for EUCRISA® (crisaborole) ointment, 2%, extending the lower age limit from 1 year to 3 months in children with mild-to-moderate atopic dermatitis. EUCRISA was previously allowed for use in adults and children over 2 years of age.
Which European Country Will Be a Lucrative Market for Atopic Dermatitis Solution Providers?
“Presence of Advanced Healthcare Infrastructure and Skilled Dermatologists in Germany”
Increasing awareness about atopic dermatitis, favorable medical reimbursement policies, and presence of well-established healthcare facilities are projected to boost the market size in Germany during the coming decade.
Technological innovations, high R&D investments, and the presence of top dermatologists are further boosting the sales of atopic dermatitis drugs in Germany.
Why is India an Emerging Market for Atopic Dermatitis Drug Producers?
“Favorable Regulatory Policies Attracting Leading Market Players”
| Attribute | India |
|---|---|
| Market Value (2024E) | US$ 711.3 Million |
| Growth Rate (2024 to 2034) | 7.7% CAGR |
| Projected Value (2034F) | US$ 1.49 Billion |
India is a big market for atopic dermatitis drug producers. The presence of favorable regulatory policies, high investments in healthcare expenditure, and rising cases of eczema are attracting atopic dermatitis drug manufacturers to establish their plants in India. Several key market players are collaborating to earn high profits in India, a high-potential economy.
- In January 2024, Glenmark and Pfizer revealed the introduction of Abrocitinib an atopic dermatitis drug in India.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which is the Prime Distribution Channel for Atopic Dermatitis Drugs?
“Affordability and Easy Availability Boosting Atopic Dermatitis Drug Sales through Retail Pharmacies”
| Attribute | Retail Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 3.76 Billion |
| Growth Rate (2024 to 2034) | 7.4% CAGR |
| Projected Value (2034F) | US$ 7.66 Billion |
According to Fact.MR, a market research and competitive intelligence provider, retail pharmacies are projected to account for 39.3% of the global market share by 2034. Retail pharmacies are expected to be the most profitable distribution channels for atopic dermatitis solutions. This can be attributed to the increasing number of retail pharmacy stores around the world and availability of small molecule drugs.
Furthermore, easy availability of therapeutic drugs at the desired location, affordability, and convenience are some other factors leading retail pharmacies to be the topmost distribution channel for atopic dermatitis solutions.
Why are Topical Atopic Dermatitis Solutions Most Widely Demanded?
“Ease of Use and Quick Results from Topical Atopic Dermatitis Solutions”
| Attribute | Topical |
|---|---|
| Segment Value (2024E) | US$ 5.78 Billion |
| Growth Rate (2024 to 2034) | 5.6% CAGR |
| Projected Value (2034F) | US$ 9.99 Billion |
Topical atopic dermatitis creams or serums are widely preferred due to their easy implantation and quick results. Direct contact of medicine to affected area aids in escalating the healing procedures and quick relief. Several skin disorders including eczema cause high irritation and inflammation near affected area. Manufacturers are focusing on the production of advanced topical atopic dermatitis drugs with escalating and prolong relief properties.
Competitive Landscape
Some of the key players in the atopic dermatitis market include AbbVie Inc., Galderma Laboratories LP, Mylan M.V., Sanofi, Novartis AG., Eli Lilly and Company (Dermira), Incyte Corporation, and Pfizer Inc.
Leading companies are investing heavily in research and development activities to develop innovative atopic dermatitis solutions. The growing demand for natural and plant-based medicinal products is one of the notable atopic dermatitis market trends. Key market players are leveraging on such trends to earn high profits. They are focused on the production of natural and organic skincare products.
- In January 2022, the United States Food and Drug Administration gave approval to Dupixent (dupilumab) for the use of children above 6 months to 5 years.
Key Segments of Atopic Dermatitis Market Research
-
By Product :
- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Biologic Therapies
- PDE-4 Inhibitors
- Antibiotics
- Antihistamines
- Emollients
-
By Mode of Administration :
- Topical
- Oral
- Injectable
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Dermatology Clinics
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Market 4. Market Overview 4.1. Introduction 4.1.1. Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Market Analysis and Forecasts, 2024-2034 5. Market Outlook 5.1. Disease Epidemiology 5.2. Pipeline Analysis 5.3. Recent Development 6. Global Market Analysis and Forecasts, by Drug Class 6.1. Introduction & Definition 6.2. Market Value Forecast by Drug Class, 2024-2034 6.2.1. Corticosteroids 6.2.2. PDE4 Inhibitors 6.2.3. Biologics 6.2.4. Skin Barrier Emollients 6.2.5. CNI Immunosuppressants 6.2.6. Others 6.3. Market Attractiveness by Drug Class 7. Global Market Analysis and Forecasts, by Distribution Channel 7.1. Introduction & Definition 7.2. Market Value Forecast by Distribution Channel, 2024-2034 7.2.1. Hospital Pharmacies 7.2.2. Retail Pharmacies 7.2.3. Online Pharmacies 7.3. Market Attractiveness by Distribution Channel 8. Global Market Analysis and Forecasts, by Region 8.1. Key Findings 8.2. Market Value Forecast by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Asia Pacific 8.2.4. Latin America 8.2.5. Middle East & Africa 8.3. Market Attractiveness by Country/Region 9. North America Market Analysis and Forecast 9.1. Introduction 9.2. Market Value Forecast by Drug Class, 2024-2034 9.2.1. Corticosteroids 9.2.2. PDE4 Inhibitors 9.2.3. Biologics 9.2.4. Skin Barrier Emollients 9.2.5. CNI Immunosuppressants 9.2.6. Others 9.3. Market Value Forecast by Distribution Channel, 2024-2034 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Market Value Forecast by Country, 2024-2034 9.4.1. U.S. 9.4.2. Canada 9.5. Market Attractiveness Analysis 9.5.1. By Drug Class 9.5.2. By Distribution Channel 9.5.3. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.2. Market Value Forecast by Drug Class, 2024-2034 10.2.1. Corticosteroids 10.2.2. PDE4 Inhibitors 10.2.3. Biologics 10.2.4. Skin Barrier Emollients 10.2.5. CNI Immunosuppressants 10.2.6. Others 10.3. Market Value Forecast by Distribution Channel, 2024-2034 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Online Pharmacies 10.4. Market Value Forecast by Country/Sub-region, 2024-2034 10.4.1. Germany 10.4.2. U.K. 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Rest of Europe 10.5. Market Attractiveness Analysis 10.5.1. By Drug Class 10.5.2. By Distribution Channel 10.5.3. By Country/Sub-region 11. Asia Pacific Market Analysis and Forecast 11.1. Introduction 11.2. Market Value Forecast by Drug Class, 2024-2034 11.2.1. Corticosteroids 11.2.2. PDE4 Inhibitors 11.2.3. Biologics 11.2.4. Skin Barrier Emollients 11.2.5. CNI Immunosuppressants 11.2.6. Others 11.3. Market Value Forecast by Distribution Channel, 2024-2034 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Online Pharmacies 11.4. Market Value Forecast by Country/Sub-region, 2024-2034 11.4.1. China 11.4.2. Japan 11.4.3. India 11.4.4. Australia & New Zealand 11.4.5. Rest of Asia Pacific 11.5. Market Attractiveness Analysis 11.5.1. By Drug Class 11.5.2. By Distribution Channel 11.5.3. By Country/Sub-region 12. Latin America Market Analysis and Forecast 12.1. Introduction 12.2. Market Value Forecast by Drug Class, 2024-2034 12.2.1. Corticosteroids 12.2.2. PDE4 Inhibitors 12.2.3. Biologics 12.2.4. Skin Barrier Emollients 12.2.5. CNI Immunosuppressants 12.2.6. Others 12.3. Market Value Forecast by Distribution Channel, 2024-2034 12.3.1. Hospital Pharmacies 12.3.2. Retail Pharmacies 12.3.3. Online Pharmacies 12.4. Market Value Forecast by Country/Sub-region, 2024-2034 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Rest of Latin America 12.5. Market Attractiveness Analysis 12.5.1. By Drug Class 12.5.2. By Distribution Channel 12.5.3. By Country/Sub-region 13. Middle East & Africa Market Analysis and Forecast 13.1. Introduction 13.2. Market Value Forecast by Drug Class, 2024-2034 13.2.1. Corticosteroids 13.2.2. PDE4 Inhibitors 13.2.3. Biologics 13.2.4. Skin Barrier Emollients 13.2.5. CNI Immunosuppressants 13.2.6. Others 13.3. Market Value Forecast by Distribution Channel, 2024-2034 13.3.1. Hospital Pharmacies 13.3.2. Retail Pharmacies 13.3.3. Online Pharmacies 13.4. Market Value Forecast by Country/Sub-region, 2024-2034 13.4.1. GCC Countries 13.4.2. South Africa 13.4.3. Rest of Middle East & Africa 13.5. Market Attractiveness Analysis 13.5.1. By Drug Class 13.5.2. By Distribution Channel 13.5.3. By Country/Sub-region 14. Competitive Landscape 14.1. Company Profiles 14.1.1. Mylan N.V. 14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.1.2. Product Portfolio 14.1.1.3. SWOT Analysis 14.1.1.4. Strategic Overview 14.1.1.5. Financial Overview 14.1.2. Pfizer, Inc. 14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.2.2. Product Portfolio 14.1.2.3. SWOT Analysis 14.1.2.4. Strategic Overview 14.1.2.5. Financial Overview 14.1.3. LEO Pharma A/S 14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.3.2. Product Portfolio 14.1.3.3. SWOT Analysis 14.1.3.4. Strategic Overview 14.1.3.5. Financial Overview 14.1.4. Teva Pharmaceutical Industries Ltd 14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.4.2. Product Portfolio 14.1.4.3. SWOT Analysis 14.1.4.4. Strategic Overview 14.1.4.5. Financial Overview 14.1.5. Sanofi 14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.5.2. Product Portfolio 14.1.5.3. SWOT Analysis 14.1.5.4. Strategic Overview 14.1.5.5. Financial Overview 14.1.6. Novartis AG 14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.6.2. Product Portfolio 14.1.6.3. SWOT Analysis 14.1.6.4. Strategic Overview 14.1.6.5. Financial Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Drug Class, 2024-2034
Table 02: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034
Table 03: Global Market Value (US$ Mn) Forecast, by Region, 2024-2034
Table 04: North America Market Value (US$ Mn) Forecast, by Country, 2024-2034
Table 05: North America Value (US$ Mn) Forecast, by Drug Class, 2024-2034
Table 06: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034
Table 07: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034
Table 08: Europe Value (US$ Mn) Forecast, by Drug Class, 2024-2034
Table 09: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034
Table 10: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034
Table 11: Asia Pacific Value (US$ Mn) Forecast, by Drug Class, 2024-2034
Table 12: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034
Table 13: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034
Table 14: Latin America Value (US$ Mn) Forecast, by Drug Class, 2024-2034
Table 15: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034
Table 16: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034
Table 17: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2024-2034
Table 18: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Snapshot
Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2024 and 2029
Figure 03: Global Market Value (US$ Mn) Forecast, 2024-2034
Figure 04: Global Market Value Share (%), by Drug Class (2024)
Figure 05: Global Market Value Share (%), by Distribution Channel (2024)
Figure 06: Global Market Value Share (%), by Region (2024)
Figure 07: Global Market Value Share Analysis, by Drug Class, 2024 and 2029
Figure 08: Global Market Attractiveness, by Drug Class, 2024-2029
Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2024-2034
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2024-2034
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biologics, 2024-2034
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Barrier Emollients, 2024-2034
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNI Immunosuppressants, 2024-2034
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2024-2034
Figure 15: Global Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2024-2034
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2024-2034
Figure 18: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2024-2034
Figure 19: Global Market Attractiveness, by Distribution Channel, 2024-2029
Figure 20: Global Market Value Share Analysis, by Region, 2024 and 2029
Figure 21: Global Market Attractiveness, by Region, 2024-2029
Figure 22: North America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034
Figure 23: North America Market Value Share (%), by Country, 2024 and 2029
Figure 24: North America Market Attractiveness, by Country, 2024-2029
Figure 25: North America Market Value Share (%), by Drug Class, 2024 and 2029
Figure 26: North America Market Attractiveness, by Drug Class, 2024-2029
Figure 27: North America Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 28: North America Market Attractiveness, by Distribution Channel, 2024-2029
Figure 29: Europe Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034
Figure 30: Europe Market Value Share (%), by Country/Sub-region, 2024 and 2029
Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2024-2029
Figure 32: Europe Market Value Share (%), by Drug Class, 2024 and 2029
Figure 33: Europe Market Attractiveness, by Drug Class, 2024-2029
Figure 34: Europe Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 35: Europe Market Attractiveness, by Distribution Channel, 2024-2029
Figure 36: Asia Pacific Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034
Figure 37: Asia Pacific Market Value Share (%), by Country/Sub-region, 2024 and 2029
Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2024-2029
Figure 39: Asia Pacific Market Value Share (%), by Drug Class, 2024 and 2029
Figure 40: Asia Pacific Market Attractiveness, by Drug Class, 2024-2029
Figure 41: Asia Pacific Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 42: Asia Pacific Market Attractiveness, by Distribution Channel, 2024-2029
Figure 43: Latin America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2027
Figure 44: Latin America Market Value Share (%), by Country/Sub-region 2024 and 2029
Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2024-2029
Figure 46: Latin America Market Value Share (%), by Drug Class, 2024 and 2029
Figure 47: Latin America Market Attractiveness, by Drug Class, 2024-2029
Figure 48: Latin America Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 49: Latin America Market Attractiveness, by Distribution Channel, 2024-2029
Figure 50: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034
Figure 51: Middle East & Africa Market Value Share (%), by Country/Sub-region 2024 and 2034
Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2024-2034
Figure 53: Middle East & Africa Market Value Share (%), by Drug Class, 2024 and 2034
Figure 54: Middle East & Africa Market Attractiveness, by Drug Class, 2024-2034
Figure 55: Middle East & Africa Market Value Share (%), by Distribution Channel, 2024 and 2034
Figure 56: Middle East & Africa Market Attractiveness, by Distribution Channel, 2024-2034
Figure 57: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2019-2023
Figure 58: Mylan N.V. R&D Expenses (US$ Mn), 2018-2020
Figure 59: Mylan N.V. Breakdown of Net Sales (%), by Region, 2020
Figure 60: Mylan N.V. Breakdown of Net Sales (%), by Business Segment, 2020
Figure 61: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020
Figure 62: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2020
Figure 63: Pfizer, Inc. R&D Expenses (US$ Mn), 2018-2020
Figure 64: LEO Pharma A/S Breakdown of Net Sales, by Region (2018)
Figure 65: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2018)
Figure 66: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2020
Figure 67: LEO Pharma A/S R&D Expenses (US$ Mn), 2018-2020
Figure 68: Sanofi Revenue (US$ Bn), 2017-2020
Figure 69: Sanofi Regional Sales Breakdown (%), 2020
Figure 70: Novartis AG Breakdown of Net Sales, by Region, 2020
Figure 71: Novartis AG Breakdown of Net Sales, by Business Segment, 2020
Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2020
Figure 73: Novartis AG R&D Expenses (US$ Mn), 2018-2020
Figure 74: Teva Pharmaceutical Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2020
Figure 75: Teva Pharmaceutical R&D Expenses (US$ Mn), 2018-2020
Figure 76: Teva Pharmaceutical Breakdown of Net Sales, by Region, 2020
Figure 77: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2020
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the atopic dermatitis market in 2024?
The global atopic dermatitis market is evaluated at US$ 12.73 billion in 2024.
What is the anticipated value of the atopic dermatitis market for 2034?
The market for atopic dermatitis is forecasted to reach US$ 19.49 billion by 2034.
What is the estimated CAGR for the atopic dermatitis market?
Demand for atopic dermatitis solutions is projected to rise at a CAGR of 4.3% from 2024 to 2034.
What is the current value of the South Korean market?
The market in South Korea is calculated at US$ 463.5 million in 2024.
Which product type is most widely used?
Demand for calcineurin inhibitors is foreseen to rise at a CAGR of 5.2% through 2034.
Who are the key producers of atopic dermatitis treatment solutions?
Some of the leading companies include Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sanofi, and Novartis AG.
Atopic Dermatitis Market